/LVCLY
LVCLY Stock - Living Cell Technologies Limited
Healthcare|BiotechnologyOTC
$0.03+24.39%
+$0.01 (+24.39%) • Jul 9
54
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.5
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.89
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.03
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LVCLY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.03 – $0.03
TARGET (TP)$0.04
STOP LOSS$0.03
RISK/REWARD1:15.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.76
52W High$0.08
52W Low$0.02
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $42,016 | $3,405 | $268,184 | $3,168 |
| Gross Profit | N/A | $41,459 | $2,662 | $218,870 | $3,168 |
| Gross Margin | N/A | 98.7% | 78.2% | 81.6% | 100.0% |
| Operating Income | $-2,200,720 | $-2,129,490 | $-2,376,050 | $-2,278,840 | $-3,145,950 |
| Net Income | $-2,095,562 | $-2,107,658 | $-1,957,300 | $-1,460,591 | $-968,469 |
| Net Margin | N/A | -5016.3% | -57483.1% | -544.6% | -30570.4% |
| EPS | $-0.01 | $-0.02 | $-0.02 | $-0.02 | $-0.02 |
Company Overview
Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Sydney, Australia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
LVCLYBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.00
Q2 2024
EPS Surprise History
Q2 20
No data
Q4 20
No data
Q2 21
No data
Q4 21
No data
Q2 22
No data
Q4 22
No data
Q2 23
No data
Q2 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | Apr 29, 2024 | — | $-0.00 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.00 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.00 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.00 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.00 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.00 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.00 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.00 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.00 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.00 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.00 | — | — |
Q2 2018 | Jun 30, 2018 | — | $0.00 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.00 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.00 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.00 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.00 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-0.00 | — | — |
Q2 2015 | Jun 30, 2015 | — | $-0.01 | — | — |
Q4 2014 | Dec 31, 2014 | — | $-0.00 | — | — |
Q2 2014 | Jun 30, 2014 | — | $-0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about LVCLY
What is LVCLY's current stock price?
Living Cell Technologies Limited (LVCLY) is currently trading at $0.03 per share. The stock has moved +24.39% today.
What is the analyst price target for LVCLY?
No analyst price targets are currently available for this stock.
What sector is Living Cell Technologies Limited in?
Living Cell Technologies Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is LVCLY's market cap?
Living Cell Technologies Limited has a market capitalization of $0.01 billion, making it a small-cap company.
Does LVCLY pay dividends?
No, Living Cell Technologies Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATBPF
Antibe Therapeutics Inc.
$0.22
Mkt Cap: $0.0B
AVEFF
Avecho Biotechnology Limited
$0.00
Mkt Cap: $0.0B
BNOEF
Bionomics Limited
$0.01
Mkt Cap: $0.0B
CRPOF
Ceapro Inc.
$0.17
Mkt Cap: $0.0B
EIGRQ
Eiger BioPharmaceuticals, Inc.
$8.50
Mkt Cap: $0.0B
LXXGF
LexaGene Holdings Inc.
$0.08
Mkt Cap: $0.0B
NOXOF
Noxopharm Limited
$0.04
Mkt Cap: $0.0B
PXXLF
Poxel S.A.
$0.25
Mkt Cap: $0.0B
RDTCF
Rapid Dose Therapeutics Corp.
$0.09
Mkt Cap: $0.0B
VRCDF
Verici Dx plc
$0.00
Mkt Cap: $0.0B
Explore stocks similar to LVCLY for comparison